Article citationsMore>>

Tedford, R.J., Hemnes, A.R., Russell, S.D., Wittstein, I.S., Mahmud, M., Zaiman, A.L., et al. (2008) PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension after Mechanical Circulatory Support. Circulation: Heart Failure, 1, 213-219.
https://doi.org/10.1161/CIRCHEARTFAILURE.108.796789

has been cited by the following article:

• TITLE: Right Ventricular Failure Following Left Ventricular Assist Device Implantation

  AUTHORS: Niraghatam Harshavardhan, Amitabh Satsangi

  KEYWORDS: Left Ventricular Assist Device (LVAD), Right Ventricular Failure (RVF), Right Ventricular Assist Device (RVAD), Right Ventricular Stroke Work Index (RVSWI), Tricuspid Regurgitation (TR)

  JOURNAL NAME: World Journal of Cardiovascular Surgery, Vol.10 No.12, December 9, 2020

  ABSTRACT: Left ventricular assist device (LVAD) is being used increasingly in recent years for end stage heart failure as a bridge to transplant (BTT) and also as a destination therapy (DT). Patients with end stage heart failure have some degree of elevated pulmonary capillary wedge pressure, causing right ventricular hypertrophy which in due course leads to decreased dilatation of the RV and fall in cardiac output & severe tricuspid regurgitation (TR) presenting with features of RV failure (RVF). Implantation of LVAD improves left heart function at the cost of right ventricular output with an incidence of 25%-30%. RVF may lead to impaired LVAD flow, difficulty in weaning from cardio-pulmonary bypass (CPB), decreased tissue perfusion and multi-organ failure. In this article we comprehended the pathophysiology leading to RVF post LVAD implantation and its preoperative predictors and the various treatment modalities for managing RVF post LVAD implantation.